Heart failure as a side effect of treatment with infliximab;Dilateret kardiomyopati som bivirkning af infliximabbehandling

Ugeskrift for Laeger

Volumn 167, Issue 39, 2005, Pages 3699-3701

  Leetmaa, Tina H ^a,b   Markenvard, John D ^b  

^a Medicinsk Afdeling ^*  (Denmark)

^b Fredericia Sygehus   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CASE REPORT; DENMARK; DISEASE EXACERBATION; DRUG INFUSION; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; SIDE EFFECT; UNITED STATES;

EID: 25844433875     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Louis A, Cleland JG, Crabbe S et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVERY and RENAISSANCE and cachexia and cholesterol in heart failure. Eur Heart Fail 2001;3:381-7.
2. Chung ES, Packer M, Lo KH et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
3. Berg PA. Risks and side effect reactions during therapy with TNF-alpha blockers. Dtsch Med Wochenschr 2004;129:1631-4.
4. De' Clari F, Salani I, Safwan E. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation 2002;105:E183.
5. Kwon HJ, Cote TR, Cuffe MS et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.